

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 9, 2013

CollabRx, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)
000-26824
(Commission
File Number)
68-0370244
(I.R.S. Employer
Identification No.)

44 Montgomery Street, Suite 800
San Francisco, CA 94104-4811
(Address of Principal Executive Offices)

(415) 248-5350
(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure.

On January 9, 2013, Thomas R. Mika, President and Chief Executive Officer of CollabRx, Inc. (the “Company”), gave investor presentations on the Company’s business at OneMedForum SF 2013 and Biotech Showcase 2013. The slides from these presentations are posted on the Company’s website, and are attached hereto as Exhibit 99.1 and shall be deemed furnished with this Current Report.

The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act.

Item 9.01. Exhibits.

[99.1](#) CollabRx, Inc. Investor Presentation – January, 2013 Slides.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 9, 2013

COLLABRX, INC.

By: /s/ Thomas R. Mika

Name: Thomas R. Mika

Title: President and Chief Executive Officer

A large black rectangular area containing the company name and presentation title in yellow and white text.

CollabRx, Inc.

Investor Presentation – January, 2013

Informing Next Generation Healthcare

Safe Harbor

This presentation and the accompanying commentary include forward-looking statements about CollabRx' anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including, but not limited to, statements as to industry trends and CollabRx' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Today's Presentation

- CollabRx' Identity, Technology and Approach
- Platform for Knowledge Integration
- Products - Released and Under Development
- Healthcare Big Data Landscape
- Product Examples
- History, Management Team, Investment Thesis
- Contacts

CollabRx, Inc.

- Data Analytics Company, founded 2008
 - NASDAQ CM: July 12, 2012 through merger
- Product-Driven, using a unique combination of Experts and Expert Systems to create a Proprietary Knowledgebase
- Inform clinical decision-making with up-to-date, actionable information on:
 - Biomarkers
 - Clinical Trials
 - Diagnostic Tests
 - Approved and Investigational New Drugs
- Focused today in Oncology for cancer diagnostics and treatment planning

Disruptive Approach and Technology

- Democratizing information by widely distributing KOL-based insights
- “Agnostic” to any particular diagnostic test - focused on relevant biomarkers, therapies, drugs and trials
- Technology platform allows scaling in all dimensions as new biomarkers identified
- Easy-to-use apps are key to accessibility and usability
- Flexible and adaptable software-centric company

Knowledge Integration drives Content Creation



Alliance Partners and Advisors Participate in Content Creation



Allen S. Lichter, MD (CEO)

"We're pleased to partner with CollabRx to leverage the Internet and social media to improve cancer treatment planning in melanoma and beyond."



Charles Roussel (CEO)

"Our collaboration with CollabRx helps us deliver on our mission to serve patients and fosters greater communication between patients and

treatment.

Over 75 medical and scientific advisors
from leading institutions



CollabRx Offers Content, Tools & Delivery Systems

Medical and Scientific Content

Dynamically updated
Best practice insights
Clinically relevant interpretations

Software and IT

Content delivery systems (“apps”)
Knowledge management systems
Decision support dashboards

Tools and Services

Artificial intelligence-based analytics
Interpretation of Big Data
Business intelligence (Pharma/Biotech)



Products – Released and Under Development

Physician / Patient Care Team

Therapy Finder Apps
Lung, Melanoma,
Colorectal,
Metastatic Breast,
Prostate, Pancreatic,
Acute Leukemia,
Sarcoma (including GIST),
GBE

Clinical Trial Matching App

Biomarker Reference Tool

Laboratory / Treatment Team

Interpretation Portal

Path Lab App
Molecular
Diagnostics
Decision Support
Workflow and
Clinical
Course Issues

Lab Dashboard (EMR)
Clinical Interpretation App

Market Size and Growth

Physician / Patient Care Team

Sponsored Apps distributed through On-Line Media:

Pharma Pre-Launch Marketing budget per drug: ~ \$50M #
Number of Drugs in Pipeline for Common Incident Cancers ~ 50
% of Budget to On-Line 10%
TAM: \$250M

Laboratory / Treatment Team

Path Lab Product only distributed by CollabRx:

Annual: 750,000 tests*
Ave. Price / Test ~ \$3,000
Ave. Price / Report ~ \$100-\$200
TAM (today): \$75M - \$150M
Growth Rate: ~47% pa**
TAM (5 yr): \$350M - \$700M

Business Models

Online Media

- License Fees
- Ad Revenue Sharing


Testing Labs

- Subscription
- Per Test Transaction Fees


Biotech/ Pharma

- Data Analysis Fees
- Consulting Fees

Healthcare Big Data Landscape



CollabRx Position in Healthcare Big Data Landscape



Therapy Finders – Web Apps for Oncologists and Patients

Individualized Lung Cancer Therapy

Therapy Finder About Therapy Finder Progress In Treatment

Therapy Finder - Professional

Powered by
CollabRx



Molecular oncology indicates that many cancers are unique or part of narrow subtypes. Molecular testing may help identify an appropriate therapy or clinical trial. Use the tool below to identify treatment options for your lung cancer patients.

Lung Cancer Stage

Early (stages 0, I and II) Stage III Stage IV
Advanced Stage

Histopathological Information

Adenocarcinoma Squamous Cell Carcinoma
 Large Cell Carcinoma Small Cell Carcinoma
 Adenosquamous NOS/Other

Metastatic Sites

Kidney Liver Adrenal Glands
 Brain/CNS Bone Other

Molecular Information

EGFR kRAS
EML4-ALK VeriStrat

clear form

Find drugs and trials →




Output Personalized to Individual Cases

- Expert insights on:
 - Targets
 - Treatment Guidelines
 - Drugs
 - Trials
 - Literature
- Links to:
 - Therapy Finder Advisor and Board
 - Learning About the Science Behind the Target

The screenshot displays the CollabRx website interface. At the top, the CollabRx logo is visible with the tagline "Raising the standard in cancer treatment". Below the logo, there are navigation links: "Back to Therapy Finder" and "Share a Link to This Page". The main content area is titled "EML4-ALK translocation: Consider Xalkori". It includes a paragraph explaining the EML4-ALK fusion and its role in lung cancer, followed by a note about the importance of histology diagnosis. A section titled "Drugs to consider:" lists Xalkori and ganespibo, providing details about their mechanisms and clinical trial status. A "References" section is also present. Below the main text, there is a "Summary" section with a table showing "Defect: EML4-ALK" and "Potentially Relevant Drug Classes: ALK Inhibitors, Hsp90 Inhibitors". At the bottom, there is a "Clinical Trials" section with a table of trials. On the right side, there is a "Therapy Finder Advisor" section featuring a photo of Ivan Tadjer, MD, PhD, and a "Learn the Science Behind This Tool" section with a diagram of the EML4-ALK fusion protein.

Clinical Interpretive Reports for Cancer Panels - Web Portal for LIFE



Life Technologies Partnership

“CollabRx has pioneered the development of a scalable platform and process to provide current, actionable, easily accessible, and highly credible knowledge at the point of care to aid physicians in developing a cancer treatment plan based on tumor molecular profiles. We are excited to include this key capability with our molecular diagnostic tests.”

- Ronnie Andrews, President
Medical Sciences, Life Technologies Corporation

CollabRx Management

- **Thomas Mika, Chairman & CEO**
 - Tegal, IMTEC, Cresap, NSF
- **George Lundberg, MD, Editor-In-Chief**
 - American Medical Association, WebMD, Medscape
- **Gavin Gordon, MBA, PhD, Head of Bus Dev & Alliances**
 - Harvard Medical School (professor; molecular pathology)
- **Smruti Vidwans, PhD, Chief Scientist**
 - McKinsey & Company (GSK, Roche), MIT, UCSF
- **Randy Gobbel, PhD, Head of Engineering**
 - PARC (XEROX), XEROX, MDL, UCSD

Investment Thesis

- **Founded 2008 by Silicon Valley Tech Entrepreneurs**
 - Approximately \$10M Invested Capital
 - Acquired by Tegal Corporation (TGAL) on July 12, 2012
- **NASDAQ CM: CLRX (as of September 27, 2012)**
 - Cash: \$6.2M as of September 30, 2012 (Q2-FY'13)
 - Liabilities: \$0.5M Note to Sellers
 - Net Operating Loss (Estimates): ~ \$100M Federal; \$50M California
 - ~ 2 Million Total Shares Outstanding; ~2.6M fully-diluted
- **Convergence of multiple mega trends**
- **Disruptive technology and approach**
- **No comparable micro-caps in this sector**
- **Goals for CY2013 - Expand strategic partnerships, product development, and product launches for initial revenue**

Contacts

**Thomas R. Mika, Chairman &
CEO**

tmika@collabrx.com

415.248.5350 (office)

415-686-2198 (mobile)

CollabRx, Inc.

44 Montgomery St., Suite 800

San Francisco, CA 94104

www.collabrx.com

NASDAQ CM: CLRX

Investor Relations Contact:

Robert Ferri

Robert Ferri Partners

580 California Street, Suite 1200

San Francisco, CA 94104

(415) 575-1589 (direct)

robert.ferri@robertferri.com

www.robertferri.com